@article{manavi_neuroprotective_2022,
	title = {Neuroprotective effects of glucagon-like peptide-1 ({GLP}-1) analogues in epilepsy and associated comorbidities},
	volume = {94},
	issn = {0143-4179},
	url = {https://www.sciencedirect.com/science/article/pii/S0143417922000257},
	doi = {10.1016/j.npep.2022.102250},
	abstract = {Epilepsy is a common neurological condition induced by losing equilibrium of different pathway as well as neurotransmitters that affects over 50 million people globally. Furthermore, long-term administration of anti-seizure medications has been associated with psychological adverse effects. Also, epilepsy has been related to an increased prevalence of obesity and called type 2 diabetes mellitus. On the other hand, GLP-1 receptors are located throughout the brain, including the hippocampus, which have been associated to majority of neurological conditions, such as epilepsy and psychiatric disorders. Moreover, the impact of different GLP-1 analogues on diverse neurotransmitter systems and associated cellular and molecular pathways as a potential therapeutic target for epilepsy and associated comorbidities has piqued curiosity. In this regard, the anticonvulsant effects of GLP-1 analogues have been investigated in various animal models and promising results such as anticonvulsants as well as cognitive improvements have been observed. For instance, GLP-1 analogues like liraglutide in addition to their possible anticonvulsant benefits, could be utilized to alleviate mental cognitive problems caused by both epilepsy and anti-seizure medication side effects. In this review and growing protective function of GLP-1 in epilepsy induced by disturbed neurotransmitter pathways and the probable mechanisms of action of GLP-1 analogues as well as the GLP-1 receptor in these effects have been discussed.},
	urldate = {2025-11-10},
	journal = {Neuropeptides},
	author = {Manavi, Mohammad Amin},
	month = aug,
	year = {2022},
	keywords = {Anti-seizure medication, Diabetes, Epilepsy, GLP-1, Liraglutide, Seizure},
	pages = {102250},
}

{"_id":"inKeqR3nM5AckpgSj","bibbaseid":"manavi-neuroprotectiveeffectsofglucagonlikepeptide1glp1analoguesinepilepsyandassociatedcomorbidities-2022","author_short":["Manavi, M. A."],"bibdata":{"bibtype":"article","type":"article","title":"Neuroprotective effects of glucagon-like peptide-1 (GLP-1) analogues in epilepsy and associated comorbidities","volume":"94","issn":"0143-4179","url":"https://www.sciencedirect.com/science/article/pii/S0143417922000257","doi":"10.1016/j.npep.2022.102250","abstract":"Epilepsy is a common neurological condition induced by losing equilibrium of different pathway as well as neurotransmitters that affects over 50 million people globally. Furthermore, long-term administration of anti-seizure medications has been associated with psychological adverse effects. Also, epilepsy has been related to an increased prevalence of obesity and called type 2 diabetes mellitus. On the other hand, GLP-1 receptors are located throughout the brain, including the hippocampus, which have been associated to majority of neurological conditions, such as epilepsy and psychiatric disorders. Moreover, the impact of different GLP-1 analogues on diverse neurotransmitter systems and associated cellular and molecular pathways as a potential therapeutic target for epilepsy and associated comorbidities has piqued curiosity. In this regard, the anticonvulsant effects of GLP-1 analogues have been investigated in various animal models and promising results such as anticonvulsants as well as cognitive improvements have been observed. For instance, GLP-1 analogues like liraglutide in addition to their possible anticonvulsant benefits, could be utilized to alleviate mental cognitive problems caused by both epilepsy and anti-seizure medication side effects. In this review and growing protective function of GLP-1 in epilepsy induced by disturbed neurotransmitter pathways and the probable mechanisms of action of GLP-1 analogues as well as the GLP-1 receptor in these effects have been discussed.","urldate":"2025-11-10","journal":"Neuropeptides","author":[{"propositions":[],"lastnames":["Manavi"],"firstnames":["Mohammad","Amin"],"suffixes":[]}],"month":"August","year":"2022","keywords":"Anti-seizure medication, Diabetes, Epilepsy, GLP-1, Liraglutide, Seizure","pages":"102250","bibtex":"@article{manavi_neuroprotective_2022,\n\ttitle = {Neuroprotective effects of glucagon-like peptide-1 ({GLP}-1) analogues in epilepsy and associated comorbidities},\n\tvolume = {94},\n\tissn = {0143-4179},\n\turl = {https://www.sciencedirect.com/science/article/pii/S0143417922000257},\n\tdoi = {10.1016/j.npep.2022.102250},\n\tabstract = {Epilepsy is a common neurological condition induced by losing equilibrium of different pathway as well as neurotransmitters that affects over 50 million people globally. Furthermore, long-term administration of anti-seizure medications has been associated with psychological adverse effects. Also, epilepsy has been related to an increased prevalence of obesity and called type 2 diabetes mellitus. On the other hand, GLP-1 receptors are located throughout the brain, including the hippocampus, which have been associated to majority of neurological conditions, such as epilepsy and psychiatric disorders. Moreover, the impact of different GLP-1 analogues on diverse neurotransmitter systems and associated cellular and molecular pathways as a potential therapeutic target for epilepsy and associated comorbidities has piqued curiosity. In this regard, the anticonvulsant effects of GLP-1 analogues have been investigated in various animal models and promising results such as anticonvulsants as well as cognitive improvements have been observed. For instance, GLP-1 analogues like liraglutide in addition to their possible anticonvulsant benefits, could be utilized to alleviate mental cognitive problems caused by both epilepsy and anti-seizure medication side effects. In this review and growing protective function of GLP-1 in epilepsy induced by disturbed neurotransmitter pathways and the probable mechanisms of action of GLP-1 analogues as well as the GLP-1 receptor in these effects have been discussed.},\n\turldate = {2025-11-10},\n\tjournal = {Neuropeptides},\n\tauthor = {Manavi, Mohammad Amin},\n\tmonth = aug,\n\tyear = {2022},\n\tkeywords = {Anti-seizure medication, Diabetes, Epilepsy, GLP-1, Liraglutide, Seizure},\n\tpages = {102250},\n}\n\n\n\n\n\n\n\n","author_short":["Manavi, M. A."],"key":"manavi_neuroprotective_2022-1","id":"manavi_neuroprotective_2022-1","bibbaseid":"manavi-neuroprotectiveeffectsofglucagonlikepeptide1glp1analoguesinepilepsyandassociatedcomorbidities-2022","role":"author","urls":{"Paper":"https://www.sciencedirect.com/science/article/pii/S0143417922000257"},"keyword":["Anti-seizure medication","Diabetes","Epilepsy","GLP-1","Liraglutide","Seizure"],"metadata":{"authorlinks":{}},"downloads":0,"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/ArthurLee1999","dataSources":["PS7iNi9NSaRnsipEv"],"keywords":["anti-seizure medication","diabetes","epilepsy","glp-1","liraglutide","seizure"],"search_terms":["neuroprotective","effects","glucagon","peptide","glp","analogues","epilepsy","associated","comorbidities","manavi"],"title":"Neuroprotective effects of glucagon-like peptide-1 (GLP-1) analogues in epilepsy and associated comorbidities","year":2022}